Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · December 27, 2022

Cytogenetic Peripheral Blood Monitoring in Azacitidine-Treated Patients With High-Risk MDS/sAML

Leukemia Research

 

Additional Info

Disclosure statements are available on the authors' profiles:

Leukemia Research
Cytogenetic peripheral blood monitoring in azacitidine treated patients with high-risk MDS/sAML: a monocentric real-world experience
Leuk. Res 2022 Dec 01;[EPub Ahead of Print], F Braulke, A Schweighöfer, J Schanz, et al

Further Reading